Skip to main content

Support and Resources for Amyvid

Download the Amyvid Billing and Coding Guide

Find details about Amyvid billing, including information on the 2024 CMS coverage decision.

DOWNLOAD

Resources that may assist in coverage authorization requests

AMYVID SAMPLE LETTER OF MEDICAL NECESSITY AMYVID SAMPLE OF APPEALS LETTER

PETNET is the exclusive manufacturer and supplier of Amyvid in the United States

PETNET representatives are available to assist with delivery, contracting, and manufacturing questions.

  • Amyvid is available for delivery multiple days per week, and over 109,000* doses have been delivered since FDA approval1
  • Over 96% reliable*† Amyvid dose delivery since FDA approval2

*As of March 2024

†Reliable is defined by a successful dose delivered to an imaging center that can be used.

CMS=Centers for Medicare & Medicaid Services.

PET=positron emission tomography.

References:

  1. Data on File. Lilly USA, LLC. DOF-AM-US-0002.
  2. Data on File. Lilly USA, LLC. DOF-AM-US-0004.

Learn about Amyvid Reader Training

AMYVID READER TRAINING

Important Safety Information

Risk for Image Misinterpretation and Other Errors
  • Errors may occur in the Amyvid estimation of brain neuritic plaque density during image interpretation
  • Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to errors. Other errors may be due to extensive brain atrophy that limits the ability to distinguish gray and white matter on the Amyvid scan as well as motion artifacts that distort the image
  • Amyvid scan results are indicative of the brain neuritic amyloid plaque content only at the time of image acquisition and a negative scan result does not preclude the development of brain amyloid in the future

Radiation Risk

  • Amyvid, similar to other radiopharmaceuticals, contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure

The most common adverse reactions reported in clinical trials were headache (1.8%), musculoskeletal pain (0.7%), blood pressure increased (0.7%), nausea (0.7%), fatigue (0.5%), and injection site reaction (0.5%)

AM HCP ISI 14SEP2022

Please see Full Prescribing Information for Amyvid.

Indication

Amyvid is a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.

Amyvid for intravenous use is supplied in multidose vials containing 500-1900 MBq/mL Florbetapir F 18.

Limitations of Use:

  • A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder
  • Safety and effectiveness of Amyvid have not been established for:
    • Predicting development of dementia or other neurologic condition
    • Monitoring responses to therapies